About ventyx biosciences inc - VTYX
Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.
VTYX At a Glance
Ventyx Biosciences, Inc.
12790 El Camino Real
San Diego, California 92130
| Phone | 1-760-593-4832 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -135,122,000.00 | |
| Sector | Health Technology | Employees | 82 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
VTYX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.613 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.385 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.191 |
VTYX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,647,829.268 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
VTYX Liquidity
| Current Ratio | 17.973 |
| Quick Ratio | 17.973 |
| Cash Ratio | 17.01 |
VTYX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -48.358 |
| Return on Equity | -54.269 |
| Return on Total Capital | -51.02 |
| Return on Invested Capital | -52.049 |
VTYX Capital Structure
| Total Debt to Total Equity | 4.249 |
| Total Debt to Total Capital | 4.076 |
| Total Debt to Total Assets | 3.873 |
| Long-Term Debt to Equity | 3.835 |
| Long-Term Debt to Total Capital | 3.678 |